High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.

The biomarker data suggest a numerical trend toward higher efficacy at the high dose versus the low dose.

also in 1,012 other papers

The reduction in fecal biomarkers, especially lactoferrin, tended to be greater and occurred in a higher proportion of patients in the high-dose group, but this did not reach statistical significance (Table 5 ).

also in 111,027 other papers